Form 4: Agios Pharmaceuticals Director Jeffrey Capello Reports Stock Unit Vesting
SEC Form 4 Filing
Director Jeffrey Capello reports the vesting of restricted stock units into common stock of Agios Pharmaceuticals.
Summary
- On June 13, 2024, Jeffrey Capello, a director of Agios Pharmaceuticals, had 1,976 restricted stock units vest into common stock.
- The transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Capello directly owns 3,953 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting scheduled vesting of stock units. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.
Stakeholder Impact
- The vesting of stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| June 13, 2023 | Restricted stock units were granted. |
| June 13, 2024 | Restricted stock units vested and converted into common stock. |
| June 17, 2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.